P. T. Bozza

Host PGD2 acting on DP2 receptor attenuates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis

This study investigates the role of PGD2 and its receptor DP2 in hepatic fibrosis caused by Schistosoma mansoni infection, finding that PGD2/DP2 signaling protects against fibrosis rather than promoting it.

Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm

This study shows that IAV or HA induces necroptosis in macrophages, contributing to cytokine storm and lung injury, and that anti-TNF treatment prevents these effects.

Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way

This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

This study identifies HCV NS5A inhibitors as SARS-CoV-2 exonuclease inhibitors and shows synergy in combination with polymerase inhibitors to enhance antiviral efficacy.

WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2

This study examines the effects of the cannabinoid agonist WIN 55,212-2 on inflammation and cell survival in human iPSC-derived cardiomyocytes infected with SARS-CoV-2, finding reduced cytokine levels and cytotoxic damage.

Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility

This study shows that inhibiting the Sigma-1 receptor with NE-100 reduces SARS-CoV-2 infection in human cardiomyocytes but also impairs cytoskeleton and contractility.

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

This study shows that lipid droplets support SARS-CoV-2 replication and inflammatory mediator production, with DGAT-1 inhibition reducing viral replication and inflammation.

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.

The paper shows elevated VIP plasma levels in severe COVID-19 patients correlate with survival and protective effects against SARS-CoV-2 in vitro.

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.